查看購物車
  • English
  • Japanese
拉丁美洲短片段和長片段NGS市場：按產品類型、工作流程、技術、應用、最終用戶和國家分類的分析和預測（2026-2036年）
市場調查報告書
商品編碼
2125002

拉丁美洲短片段和長片段NGS市場：按產品類型、工作流程、技術、應用、最終用戶和國家分類的分析和預測（2026-2036年）

Latin America Short- and Long-Read NGS Market: Focus on Product Type, Workflow, Technology, Application, End User, and Country Analysis Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 204 Pages | 商品交期: 1-5個工作天內

價格

拉丁美洲短片段和長片段 NGS 市場在 2025 年的初始估值為 1.418 億美元，但預計到 2036 年將達到 4.415 億美元，預計從 2026 年到 2036 年將呈現 10.90% 的顯著複合年成長率。

關鍵市場統計數據
預測期 2026-2036
2026年市場規模 1.569億美元
2036年的預測 4.415億美元
複合年成長率 10.9%

拉丁美洲的短片段和長片段NGS市場正從分散且依賴外部資源的定序環境，轉向更在地化、應用主導和工作流程導向的基因組學生態系統。由於其成熟的應用基礎、擴充性、成本效益以及在常規臨床和研究工作流程中的廣泛應用，短片段定序仍然是市場的主要組成部分。

長片段定定序和可攜式奈米孔定序在公共衛生、科研和國家實驗室等領域正逐漸廣泛應用。這些領域在長片段、即時分析、靈活部署以及對感染疾病爆發的快速反應等方面展現出顯著價值。因此，一種混合生態系統正在形成：短片段定序平台支撐著大部分常定序工作，而長片段定序技術則在需要長片段、即時定序或更完整基因組表徵的應用中發揮補充作用。

該生態系統涵蓋定序平台供應商、常規耗材和工作流程供應商、樣品製備和靶向濃縮供應商、生物資訊學和分析平台，以及支援這些平台的自動化和數據基礎設施。隨著實驗室向一體化的「從樣本到報告」工作流程發展，擁有強大的產品生態系統、本地支援、培訓能力和生物資訊整合能力的供應商將更有利於滿足持續成長的市場需求。

市場概覽

拉丁美洲的短片段定序市場正受到以下因素的影響：癌症和感染疾病負擔日益加重、腫瘤學中分子譜分析的應用日益廣泛、病原體監測的持續需求，以及對罕見疾病診斷、群體基因組學、生物多樣性研究和精準公共衛生日益成長的興趣。

透過公共計畫、區域監測網路、廠商主導的培訓中心以及與私人實驗室的合作，本地基因組分析基礎設施正在不斷擴展。在巴西、墨西哥、哥倫比亞、阿根廷、智利和其他拉丁美洲國家，國家定序和生物資訊能力正透過公共衛生舉措、國家基因組計畫、區域參考檢查室以及私人實驗室的採用而逐步建構。

這種轉變推動了對定序設備、耗材、樣品製備盒、流動池、定序試劑、自動化系統、數據平台和分析軟體的需求成長。然而，生物資訊學能力的差異、熟練人員的短缺、工作流程檢驗的挑戰、檢體品質問題以及先進定序基礎設施取得途徑的差異仍然是阻礙因素。

對產業的影響

拉丁美洲的短片段和長片段NGS市場呈現出多層次的競爭格局，涵蓋定序平台供應商、工作流程支援公司和生物資訊服務提供者。在短片段定序領域，Illumina、Thermo Fisher Scientific和MGI Tech分別在合成定定序、半導體定序和DNA奈米球定序仍是主要競爭對手。同時，Oxford Nanopore Technologies plc和Pacific Biosciences of California, Inc.正透過即時定序、便攜性、高精度長片段和複雜基因組分析等差異化價值提案進軍長片段定序領域，而MGI Tech Co., Ltd.的CycloneSEQ產品組合則為該地區的技術選擇帶來了一種新區域的技術格局。

此外，競爭範圍已從定序儀器擴展到更廣泛的NGS工作流程，這提升了在樣品製備、靶向序列捕獲、自動化、數據分析和解讀等領域運作的公司策略重要性。安捷倫科技公司（Agilent Technologies, Inc.）、凱傑公司（QIAGEN NV）、Revvity公司、丹納赫公司（Danaher Corporation）和新英格蘭生物實驗室（New England Biolabs）提供整體的耗材和工作流程支持產品，而SOPHiA GENETICS SA和凱傑公司則受益於對可擴展資訊學的需求日益成長。羅氏公司（F. Hoffmann-La Roche）憑藉其專注於腫瘤學的工作流程組合和可擴展定序平台，進一步鞏固了其競爭優勢。隨著拉丁美洲的實驗室從單一儀器部署轉向更標準化的「從樣本到報告」工作流程，競爭優勢預計將越來越依賴將定定序技術與自動化、耗材、生物資訊、培訓和本地技術支援相結合的能力。

目錄

第1章：拉丁美洲短片段與長片段NGS市場：產業展望

  • 市場概覽與生態系統
  • NGS工作流程及挑戰
  • 監理情勢
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
  • 專利分析
    • 按年份
    • 國家
  • 價格分析
    • NGS技術的價格趨勢
    • 裝置
    • 成套工具
  • 基因組研究和資助舉措
    • 國家
    • 按機構類型分類
    • 研究領域
  • 前景
    • 新興科技的發展趨勢
    • 長片段定定序的發展
    • 人工智慧與生物資訊學的融合
    • 臨床應用領域的拓展
    • 拉丁美洲的市場機遇
  • 市場趨勢
    • 影響分析
    • 拉丁美洲部分研究和公共衛生領域早期過渡到長片段可攜式奈米定序
    • 從外部參考定定序基於國家和地區中心的基因組監測。
  • 市場動態
    • 促進因素、挑戰和機會：當前和未來影響評估
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章 產品類型

  • 短片段NGS市場
    • 消耗品
    • 裝置
    • 軟體
  • 長片段NGS市場
    • 消耗品
    • 裝置
    • 軟體

第3章 工作流程

  • 樣品和樣品製備
  • 定序
  • 數據分析

第4章 技術

  • 短片段定序技術
    • 合成定定序
    • 半導體定序
    • DNA奈米球定序
  • 長片段定序技術
    • 單分子即時定序
    • 奈米孔定序

第5章 方法

  • 全基因測序
  • 全EXOME定序
  • RNA定序
  • 表觀遺傳定序
  • 標靶定序
  • 總體基因體學
  • 其他

第6章 應用

  • 研究
    • 腫瘤學
    • 群體基因組學
    • 感染疾病
    • 微生物組研究
    • 其他研究領域
  • 臨床
    • 腫瘤學
    • 循環系統
    • 神經病學
    • 遺傳性疾病
    • 感染疾病
    • 生殖醫學和產前護理
    • 其他臨床用途

第7章 最終用戶

  • 醫院和診斷中心
  • 學術和研究機構
  • 製藥和生物技術公司
  • 其他最終用戶

第8章 區域

  • 區域概況
  • 巴西
    • 國家概況
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
      • 依產品類型
      • 透過技術
      • 基於工作流程
      • 用途別
      • 透過方法
    • 裝置量
    • 測試次數
  • 墨西哥
    • 國家概況
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
      • 依產品類型
      • 透過技術
      • 基於工作流程
      • 用途別
      • 透過方法
    • 裝置量
    • 測試次數
  • 阿根廷
    • 國家概況
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
      • 依產品類型
      • 透過技術
      • 基於工作流程
      • 用途別
      • 透過方法
    • 裝置量
    • 測試次數
  • 智利
    • 國家概況
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
      • 依產品類型
      • 透過技術
      • 基於工作流程
      • 用途別
      • 透過方法
    • 裝置量
    • 測試次數
  • 哥倫比亞
    • 國家概況
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
      • 依產品類型
      • 透過技術
      • 基於工作流程
      • 用途別
      • 透過方法
    • 裝置量
    • 測試次數
  • 其他拉丁美洲國家
    • 國家概況
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
      • 依產品類型
      • 透過技術
      • 基於工作流程
      • 用途別
      • 透過方法
    • 裝置量
    • 測試次數

第9章：競爭標桿分析與公司概況

  • 企業市場占有率分析
  • 科技趨勢
  • 產品基準測試
    • 依產品類型
    • 透過技術
  • 拉丁美洲短片段與長片段NGS基礎建設的發展趨勢
  • 關鍵策略和趨勢
  • 公司簡介
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • MGI Tech Co., Ltd.
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies plc
    • F. Hoffmann-La Roche Ltd.
    • Agilent Technologies, Inc.
    • Revvity Inc.
    • QIAGEN NV
    • Danaher Corporation
    • SOPHiA GENETICS SA
    • New England Biolabs

第10章：調查方法

This report can be delivered within 1 working day.

Introduction of the Latin America Short- and Long-Read NGS Market

The Latin America short- and long-read NGS market, initially valued at $141.8 million in 2025, is projected to grow substantially, reaching $441.5 million by 2036, with a remarkable compound annual growth rate (CAGR) of 10.90% from 2026 to 2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$156.9 Million
2036 Forecast$441.5 Million
CAGR10.9%

The Latin America short- and long-read NGS market is evolving from a fragmented and externally dependent sequencing landscape toward a more localized, application-driven, and workflow-oriented genomics ecosystem. Short-read sequencing continues to form the backbone of the market because of its established installed base, scalability, cost-efficiency, and broad use in routine clinical and research workflows.

Long-read sequencing and portable nanopore sequencing are gaining selective traction in public health, research, and national institute settings where longer reads, real-time analysis, flexible deployment, and rapid outbreak response provide clear value. The resulting ecosystem is hybrid; short-read platforms support the majority of routine sequencing volume, while long-read technologies complement them in applications requiring longer reads, real-time sequencing, or more complete genome characterization.

The ecosystem includes sequencing platform providers, recurring consumables and workflow suppliers, library preparation and target enrichment providers, bioinformatics and interpretation platforms, and supporting automation and data infrastructure. As laboratories move toward integrated sample-to-report workflows, vendors with strong product ecosystems, local support, training capabilities, and bioinformatics integration are positioned to capture recurring demand.

Market Introduction

The Latin America short- and long-read NGS market is being shaped by the growing burden of cancer and infectious diseases, the increasing use of molecular profiling in oncology, the continued need for pathogen surveillance, and expanding interest in rare disease diagnosis, population genomics, biodiversity research, and precision public health.

Local genomics infrastructure is expanding through public programs, regional surveillance networks, vendor-led training centers, and private laboratory partnerships. Brazil, Mexico, Colombia, Argentina, Chile, and other Latin American countries are gradually building domestic sequencing and bioinformatics capabilities through public health initiatives, national genomics programs, regional reference laboratories, and commercial laboratory adoption.

This shift is increasing demand for sequencing instruments, recurring consumables, library preparation kits, flow cells, sequencing reagents, automation systems, data platforms, and interpretation software. However, bioinformatics capacity gaps, skilled workforce shortages, workflow validation challenges, sample quality issues, and uneven access to advanced sequencing infrastructure remain constraints.

Industrial Impact

The Latin America short- and long-read NGS market is being shaped by a multi-layered competitive landscape comprising sequencing platform vendors, workflow support companies, and bioinformatics providers. In short-read sequencing, Illumina, Inc., Thermo Fisher Scientific Inc., and MGI Tech Co., Ltd. remain the principal competitors across sequencing-by-synthesis, semiconductor sequencing, and DNA nanoball sequencing, respectively. At the same time, Oxford Nanopore Technologies plc and Pacific Biosciences of California, Inc. are expanding the long-read segment through differentiated value propositions around real-time sequencing, portability, high-accuracy long reads, and complex genomic analysis, while MGI Tech Co., Ltd.'s CycloneSEQ portfolio introduces an additional nanopore-based pathway into the regional technology landscape.

At the same time, competition is extending beyond sequencing instruments toward the broader NGS workflow, increasing the strategic importance of companies operating across library preparation, target enrichment, automation, data analysis, and interpretation. Agilent Technologies, Inc., QIAGEN N.V., Revvity Inc., Danaher Corporation, and New England Biolabs are positioned across recurring consumables and workflow-support products, while SOPHiA GENETICS SA and QIAGEN N.V. are benefiting from the growing need for scalable bioinformatics and interpretation capabilities. F. Hoffmann-La Roche Ltd. adds another competitive layer through its oncology-focused workflow portfolio and sequencing-by-expansion platform. As Latin American laboratories move from isolated instrument adoption toward more standardized sample-to-report workflows, competitive advantage is expected to increasingly depend on the ability to combine sequencing technology with automation, consumables, bioinformatics, training, and local technical support.

Market Segmentation:

Segmentation 1: By Product Type

  • Short-Read NGS Market
    • Consumables
    • Instruments
    • Software
  • Long-Read NGS Market
    • Consumables
    • Instruments
    • Software

Consumables Segment to Dominate Latin America Short- and Long-Read NGS Market (by Product Type)

In 2025, consumables are expected to account for the largest share of both the short-read and long-read NGS markets in Latin America. This is primarily driven by their recurring use across every sequencing run, including sequencing reagents, flow cells, library preparation kits, and other workflow-specific consumables. Consumable demand scales directly with sequencing volume and platform utilization. The broader installed base and higher routine testing volumes support consumable demand in short-read sequencing, while the gradual transition of long-read sequencing from pilot studies toward broader research and specialized applications is expected to increase recurring reagent and flow-cell consumption over the forecast period.

Segmentation 2: By Workflow

  • Sample Preparation and Library Preparation
  • Sequencing
  • Analysis

Sequencing Segment to Dominate Latin America Short- and Long-Read NGS Market (by Workflow)

In 2025, on the basis of workflow, sequencing is expected to capture the largest share of the Latin America short- and long-read NGS market by workflow, as this segment includes the highest-value recurring consumables such as sequencing reagents, flow cells, chips, SMRT Cells, and run-specific kits, along with instrument utilization. In addition to this, data analysis will gain importance as NGS adoption expands, yet its revenue contribution is likely to remain smaller than sequencing and preparation workflows due to lower per-sample monetization and greater use of bundled or platform-linked software.

Segmentation 3: By Technology

  • Short-Read Sequencing Technologies
  • Long-Read Sequencing Technologies

Short-Read Sequencing Technologies Segment to Dominate Latin America Short- and Long-Read NGS Market (by Technology)

In 2025, on the basis of technology, the short-read sequencing technologies segment is expected to capture the largest share of the Latin America short- and long-read NGS market. This is supported by the broader installed base, higher routine sequencing volumes, lower cost per sample, and wider use of short-read platforms across oncology, infectious disease, reproductive health, inherited disease, and research applications. Short-read sequencing also benefits from a mature ecosystem of consumables, library preparation products, target enrichment panels, and bioinformatics tools, which supports recurring demand across laboratories. Long-read sequencing is expected to grow at a faster pace in specialized applications such as structural variant analysis, complex genome assembly, rare disease research, and pathogen genomics; however, its share is likely to remain smaller due to a more limited installed base, higher workflow complexity, and concentration in advanced research and translational genomics centers.

Segmentation 4: By Method

  • Whole-Genome Sequencing
  • Whole-Exome Sequencing
  • RNA Sequencing
  • Epigenetic Sequencing
  • Targeted Sequencing
  • Metagenomic Sequencing
  • Others

Whole-Genome Sequencing Segment to Dominate Latin America Short- and Long-Read NGS Market (by Method)

In 2025, on the basis of method, whole-genome sequencing is expected to capture the largest share of the Latin America short- and long-read NGS market. This is supported by its broad use across population genomics, oncology research, rare disease studies, infectious disease surveillance, microbial genomics, agricultural genomics, and biodiversity programs, along with higher sequencing-output requirements per sample compared with exome, RNA, epigenetic, and metagenomic workflows. Whole genome sequencing also benefits from adoption across both short-read and long-read platforms, making it relevant to a wider range of instrument and consumable portfolios. Whole exome sequencing is expected to remain important in clinical genetics and rare disease applications, while RNA sequencing, epigenetic sequencing, and metagenomics are likely to grow from a smaller base due to their more specialized use cases.

Segmentation 5: By Application

  • Clinical
  • Research

Research Segment to Dominate Latin America Short- and Long-Read NGS Market (by Application)

In 2025, on the basis of application, research applications are expected to capture the larger share of the Latin America short- and long-read NGS market due to the region's strong reliance on academic institutions, government-funded genomics programs, and pharmaceutical research for applications such as cancer genomics, infectious disease surveillance, and population genetics. In contrast, routine clinical adoption remains comparatively limited because of reimbursement constraints, uneven access to genomic testing, and the gradual integration of NGS into standard healthcare practice across many Latin American countries.

Segmentation 6: By End User

  • Hospitals and Diagnostic Centers
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Others

Academic and Research Institutes Segment to Dominate Latin America Short- and Long-Read NGS Market (by End User)

In 2025, on the basis of end user, academic and research institutes are expected to capture the largest value share of the Latin America short- and long-read NGS market owing to substantial government and international funding for genomics research, infectious disease surveillance, cancer genomics, and population genetics. Furthermore, a significant proportion of high-throughput sequencing infrastructure in the region is concentrated within universities and public research organizations, making them the primary users of NGS technologies.

Recent Developments in the Latin America Short- and Long-Read NGS Market

  • In May 2026, MGI Tech Co., Ltd. launched integrated SEQ ALL metagenomic solutions for Andes Hantavirus response, combining DNBSEQ short-read sequencing with CycloneSEQ long-read sequencing. The offering positioned MGI across both short- and long-read infectious disease surveillance workflows and expanded its application relevance for Latin American public health genomics.
  • In March 2026, MGI Tech Co., Ltd. partnered with NeoGenomica to expand access to high-throughput genomics in Brazil. The collaboration used DNBSEQ-T7 and MGISP automation and included technical training, knowledge exchange, and best-practice support, which helped scale whole-genome, oncology, and rare disease sequencing capacity.
  • In November 2025, SOPHiA GENETICS SA participated in AMGH 2025 in Puerto Vallarta, Mexico, covering the Mexican Association of Human Genetics Congress and the Latin American Congress of Human Genetics. The company showcased SOPHiA DDM to regional genetics stakeholders, which supported market education and customer development for NGS data analytics in Latin America.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

  • Rising Cancer and Infectious Disease Burden Driving Demand for Next-Generation Sequencing and Associated Products: The increasing burden of cancer and infectious diseases is creating sustained demand for NGS products across Latin America. Oncology is driving clinical demand through molecular tumor profiling, DNA/RNA panels, WES/WGS, liquid biopsy, hereditary cancer testing, and variant interpretation software. Infectious diseases are strengthening public health demand for pathogen sequencing, dengue serotype monitoring, tuberculosis resistance profiling, outbreak investigation, antimicrobial resistance characterization, and genomic surveillance. As testing and surveillance volumes expand, the Latin America short- and long-read NGS market is expected to see recurring demand for sequencing reagents, flow cells, library preparation kits, sample preparation products, quality-control materials, and NGS-specific bioinformatics platforms. Overall, the disease burden across oncology and infectious diseases is expected to remain a key driver of demand for NGS instruments, consumables, and software in the region.
  • Expansion of Local Genomics Infrastructure through Public Programs, Vendor Hubs, and Strategic Partnerships: The recent developments across Brazil, Colombia, Mexico, and Argentina show that local infrastructure expansion is becoming an active demand driver for the Latin America NGS market. Public programs such as Genomas Brasil, GenSUS, and SUS whole-exome sequencing are institutionalizing genomics within public health and precision medicine, creating sustained demand for sequencing capacity and interpretation tools. Vendor-led centers from MGI Tech Co., Ltd. and Illumina are improving customer readiness through local training, demonstrations, automation access, workflow evaluation, and technical support. Private partnerships such as MGI-Gencell and SOPHiA-Argenetics indicate that commercial laboratories are scaling sequencing and analytics capacity for WES, WGS, oncology, and hematology workflows. Together, these developments are strengthening the regional NGS installed base and increasing recurring demand for instruments, consumables, automated sample preparation systems, and NGS-specific software.
  • Expansion of Local Genomic Data Generation and Population-Scale Sequencing Programs Driving NGS Adoption: For the Latin America short- and long-read NGS market, population-scale genomic data generation drives demand across the full sequencing workflow. National genomic databases, rare disease cohorts, oncology datasets, pharmacogenomics studies, and public health genomics programs require sample preparation products, library preparation kits, sequencing reagents, flow cells, WES/WGS workflows, automation systems, data storage platforms, bioinformatics pipelines, variant curation tools, and interpretation software. The impact extends beyond one-time instrument placement, as ongoing genomic dataset development creates recurring demand for consumables, sequencing runs, quality-control materials, software, and data-management infrastructure. As these programs expand, NGS adoption is expected to strengthen across public health programs, research institutions, reference laboratories, and specialized clinical centers in Latin America.

Market Challenges

  • Bioinformatics, Skilled Workforce, and Workflow Implementation Gaps Limiting NGS Scalability: Bioinformatics, workforce, and workflow readiness gaps limit both the adoption of new NGS platforms and the utilization of installed systems in Latin America. These constraints reduce the market's ability to convert clinical, research, and public health demand into sustained product usage. As a result, the restraint directly affects pull-through demand for sequencing reagents, flow cells, library preparation kits, sample preparation products, quality-control materials, and NGS-specific software. Wider adoption of NGS across the region will require parallel investment in technical training, bioinformatics infrastructure, workflow standardization, sample quality management, and clinical reporting capacity.

Market Opportunities

  • Expansion of Integrated Sample-to-Report NGS Workflow Bundles for Latin American Laboratories: Integrated sample-to-report NGS workflow solutions represent a high-value product opportunity in Latin America. The region's laboratories are increasingly looking for solutions that reduce operational complexity and enable scalable sequencing across clinical and research applications. Workflow-led models that combine sequencers, automation systems, data platforms, bioinformatics, training, and local support can help laboratories improve throughput and reduce dependence on external sequencing providers. For vendors, the opportunity extends beyond one-time instrument sales and creates recurring revenue potential across consumables, reagents, flow cells, automation products, software, data platforms, and service support.

How can this report add value to an organization?

Product/Innovation Strategy: The Latin America short- and long-read NGS market has been segmented across product type, workflow, technology, method, application, end user, and country. This segmentation helps organizations assess demand across short- and long-read instruments, consumables, and software, while also evaluating adoption across sample and library preparation, sequencing, and data-analysis workflows. By examining technology-level opportunities across sequencing-by-synthesis, semiconductor sequencing, DNA nanoball sequencing, SMRT sequencing, and nanopore sequencing, alongside methods such as whole-genome sequencing, whole-exome sequencing, RNA sequencing, epigenetic sequencing, targeted sequencing, and metagenomics.

Growth/Marketing Strategy: The Latin America short- and long-read NGS market is being driven by the localization of genomic testing, expansion of public and private sequencing infrastructure, increasing cancer and infectious disease burden, population-scale genomic programs, and growing adoption of sequencing across research, public health, and selected clinical applications. The report helps organizations identify high-potential customer groups and application areas, prioritize markets such as Brazil, Mexico, Argentina, Chile, and Colombia, and assess opportunities across academic and research institutes, hospitals and diagnostic centers, pharmaceutical and biotechnology companies, and other end users.

Competitive Strategy: The Latin America short- and long-read NGS market includes sequencing-platform companies, long-read specialists, workflow-support companies, and bioinformatics providers competing across instruments, consumables, software, and data interpretation. The report helps organizations benchmark competitor positioning across short-read and long-read technologies, assess differences in throughput, workflow simplicity, installed-base expansion, and local support, and identify opportunities for partnerships, portfolio expansion, and workflow integration. It also supports competitive decision-making by outlining how differentiation is shifting from instrument placement alone toward integrated workflows, recurring consumables, automation, bioinformatics, turnaround time, training, and technical service as laboratories move toward more complete sample-to-report NGS ecosystems.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the Latin America short- and long-read NGS market. For market size estimation, 2025 has been considered the base year, and 2026 to 2036 the forecast period.
  • Data on the portability type was considered from national and international organizations.
  • Publicly traded companies involved in the development of medical image analytics solutions also provided data.
  • Industry research papers, patents, and advancements in related technologies highlighted emerging trends and growth opportunities in the market. Proxy indicators were employed where direct data were unavailable.
  • Databases such as Bloomberg and governmental statistical portals offering insights on raw material usage, innovative technologies, and market trends were extensively utilized.
  • Technologies currently used are expected to persist through the forecast period 2026-2036.
  • The economic downturn in the future was not taken into consideration for market estimation and forecast.

Primary Research

The primary sources involve industry experts and key stakeholders across the healthcare and medical imaging ecosystem, including medical image analytics providers, medical device manufacturers, radiology service providers, and healthcare institutions. Stakeholders such as hospitals, imaging centers, and teleradiology providers have been consulted to validate adoption trends and clinical utility. Respondents, including CEOs, vice presidents, product and marketing directors, and technology and innovation leaders, have been interviewed to obtain and verify both qualitative and quantitative insights for this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • MGI Tech Co., Ltd.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies plc
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • Revvity Inc.
  • QIAGEN N.V.
  • Danaher Corporation
  • SOPHiA GENETICS SA
  • New England Biolabs

Table of Contents

Executive Summary

Scope and Definition

1 Latin America Short- and Long-Read NGS Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
  • 1.2 NGS Workflow and Pain Points
  • 1.3 Regulatory Landscape
    • 1.3.1 Brazil
    • 1.3.2 Mexico
    • 1.3.3 Argentina
    • 1.3.4 Colombia
  • 1.4 Patent Analysis
    • 1.4.1 By Year
    • 1.4.2 By Country
  • 1.5 Pricing Analysis
    • 1.5.1 Pricing Trends in NGS Technologies
    • 1.5.2 Instruments
    • 1.5.3 Kits
  • 1.6 Genomics Research and Funding Initiatives
    • 1.6.1 By Country
    • 1.6.2 By Institution Type
    • 1.6.3 Research Area
  • 1.7 Future Outlook
    • 1.7.1 Emerging Technology Trends
    • 1.7.2 Growth of Long-Read Sequencing
    • 1.7.3 Integration of AI and Bioinformatics
    • 1.7.4 Expansion of Clinical Applications
    • 1.7.5 Market Opportunities for Latin America
  • 1.8 Market Trends
    • 1.8.1 Impact Analysis
    • 1.8.2 Early Shift toward Long-Read and Portable Nanopore Sequencing in Selected Latin American Research and Public Health Settings
    • 1.8.3 Shift from External Reference Sequencing to In-Country and Regional Hub-Based Genomic Surveillance
  • 1.9 Market Dynamics
    • 1.9.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
    • 1.9.2 Market Drivers
      • 1.9.2.1 Rising Cancer and Infectious Disease Burden Driving Demand for Next-Generation Sequencing and Associated Products
      • 1.9.2.2 Expansion of Local Genomics Infrastructure through Public Programs, Vendor Hubs, and Strategic Partnerships
      • 1.9.2.3 Expansion of Local Genomic Data Generation and Population-Scale Sequencing Programs Driving NGS Adoption
    • 1.9.3 Market Challenges
      • 1.9.3.1 Bioinformatics, Skilled Workforce, and Workflow Implementation Gaps Limiting NGS Scalability
    • 1.9.4 Market Opportunities
      • 1.9.4.1 Expansion of Integrated Sample-to-Report NGS Workflow Bundles for Latin American Laboratories

2 Product Type

  • 2.1 Short-Read NGS Market
    • 2.1.1 Consumables
    • 2.1.2 Instruments
    • 2.1.3 Software
  • 2.2 Long-Read NGS Market
    • 2.2.1 Consumables
    • 2.2.2 Instruments
    • 2.2.3 Software

3 Workflow

  • 3.1 Sample and Library Preparation
  • 3.2 Sequencing
  • 3.3 Data Analysis

4 Technology

  • 4.1 Short-Read Sequencing Technologies
    • 4.1.1 Sequencing by Synthesis
    • 4.1.2 Semiconductor Sequencing
    • 4.1.3 DNA Nanoball Sequencing
  • 4.2 Long-Read Sequencing Technologies
    • 4.2.1 Single-Molecule Real-Time Sequencing
    • 4.2.2 Nanopore Sequencing

5 Method

  • 5.1 Whole-Genome Sequencing
  • 5.2 Whole-Exome Sequencing
  • 5.3 RNA Sequencing
  • 5.4 Epigenetic Sequencing
  • 5.5 Targeted Sequencing
  • 5.6 Metagenomics
  • 5.7 Others

6 Application

  • 6.1 Research
    • 6.1.1 Oncology
    • 6.1.2 Population Genomics
    • 6.1.3 Infectious Diseases
    • 6.1.4 Microbiome Research
    • 6.1.5 Other Research Applications
  • 6.2 Clinical
    • 6.2.1 Oncology
      • 6.2.1.1 Hematologic Malignancies
      • 6.2.1.2 Solid Tumors
    • 6.2.2 Cardiovascular
    • 6.2.3 Neurological
    • 6.2.4 Inherited Genetic Diseases
    • 6.2.5 Infectious Diseases
    • 6.2.6 Reproductive Health and Prenatal
    • 6.2.7 Other Clinical Applications

7 End User

  • 7.1 Hospitals and Diagnostic Centers
  • 7.2 Academic and Research Institutes
  • 7.3 Pharmaceutical and Biotechnology Companies
  • 7.4 Other End Users

8 Region

  • 8.1 Regional Summary
  • 8.2 Brazil
    • 8.2.1 Country Overview
    • 8.2.2 Driving Factors for Market Growth
    • 8.2.3 Factors Challenging the Market
    • 8.2.4 Market Sizing and Forecast
      • 8.2.4.1 By Product Type
      • 8.2.4.2 By Technology
      • 8.2.4.3 By Workflow
      • 8.2.4.4 By Application
      • 8.2.4.5 By Method
    • 8.2.5 Installed Base
    • 8.2.6 Testing Volume
  • 8.3 Mexico
    • 8.3.1 Country Overview
    • 8.3.2 Driving Factors for Market Growth
    • 8.3.3 Factors Challenging the Market
    • 8.3.4 Market Sizing and Forecast
      • 8.3.4.1 By Product Type
      • 8.3.4.2 By Technology
      • 8.3.4.3 By Workflow
      • 8.3.4.4 By Application
      • 8.3.4.5 By Method
    • 8.3.5 Installed Base
    • 8.3.6 Testing Volume
  • 8.4 Argentina
    • 8.4.1 Country Overview
    • 8.4.2 Driving Factors for Market Growth
    • 8.4.3 Factors Challenging the Market
    • 8.4.4 Market Sizing and Forecast
      • 8.4.4.1 By Product Type
      • 8.4.4.2 By Technology
      • 8.4.4.3 By Workflow
      • 8.4.4.4 By Application
      • 8.4.4.5 By Method
    • 8.4.5 Installed Base
    • 8.4.6 Testing Volume
  • 8.5 Chile
    • 8.5.1 Country Overview
    • 8.5.2 Driving Factors for Market Growth
    • 8.5.3 Factors Challenging the Market
    • 8.5.4 Market Sizing and Forecast
      • 8.5.4.1 By Product Type
      • 8.5.4.2 By Technology
      • 8.5.4.3 By Workflow
      • 8.5.4.4 By Application
      • 8.5.4.5 By Method
    • 8.5.5 Installed Base
    • 8.5.6 Testing Volume
  • 8.6 Colombia
    • 8.6.1 Country Overview
    • 8.6.2 Driving Factors for Market Growth
    • 8.6.3 Factors Challenging the Market
    • 8.6.4 Market Sizing and Forecast
      • 8.6.4.1 By Product Type
      • 8.6.4.2 By Technology
      • 8.6.4.3 By Workflow
      • 8.6.4.4 By Application
      • 8.6.4.5 By Method
    • 8.6.5 Installed Base
    • 8.6.6 Testing Volume
  • 8.7 Rest-of-Latin America
    • 8.7.1 Country Overview
    • 8.7.2 Driving Factors for Market Growth
    • 8.7.3 Factors Challenging the Market
    • 8.7.4 Market Sizing and Forecast
      • 8.7.4.1 By Product Type
      • 8.7.4.2 By Technology
      • 8.7.4.3 By Workflow
      • 8.7.4.4 By Application
      • 8.7.4.5 By Method
    • 8.7.5 Installed Base
    • 8.7.6 Testing Volume

9 Competitive Benchmarking and Company Profiles

  • 9.1 Company Share Analysis
  • 9.1 Technology Landscape
  • 9.2 Product Benchmarking
    • 9.2.1 By Product Type
    • 9.2.2 By Technology
  • 9.3 Latin America Short-and Long-Read NGS Infrastructure Landscape
  • 9.4 Key Strategies and Developments
  • 9.5 Company Profiles
    • 9.5.1 Illumina, Inc.
      • 9.5.1.1 Overview
      • 9.5.1.2 Top Products
      • 9.5.1.3 Top Competitors
      • 9.5.1.4 Key Personnel
      • 9.5.1.5 Analyst View
    • 9.5.2 Thermo Fisher Scientific Inc.
      • 9.5.2.1 Overview
      • 9.5.2.2 Top Products
      • 9.5.2.3 Top Competitors
      • 9.5.2.4 Key Personnel
      • 9.5.2.5 Analyst View
    • 9.5.3 MGI Tech Co., Ltd.
      • 9.5.3.1 Overview
      • 9.5.3.2 Top Products
      • 9.5.3.3 Top Competitors
      • 9.5.3.4 Key Personnel
      • 9.5.3.5 Analyst View
    • 9.5.4 Pacific Biosciences of California, Inc.
      • 9.5.4.1 Overview
      • 9.5.4.2 Top Products
      • 9.5.4.3 Top Competitors
      • 9.5.4.4 Key Personnel
      • 9.5.4.5 Analyst View
    • 9.5.5 Oxford Nanopore Technologies plc
      • 9.5.5.1 Overview
      • 9.5.5.2 Top Products
      • 9.5.5.3 Top Competitors
      • 9.5.5.4 Key Personnel
      • 9.5.5.5 Analyst View
    • 9.5.6 F. Hoffmann-La Roche Ltd.
      • 9.5.6.1 Overview
      • 9.5.6.2 Top Products
      • 9.5.6.3 Top Competitors
      • 9.5.6.4 Key Personnel
      • 9.5.6.5 Analyst View
    • 9.5.7 Agilent Technologies, Inc.
      • 9.5.7.1 Overview
      • 9.5.7.2 Top Products
      • 9.5.7.3 Top Competitors
      • 9.5.7.4 Key Personnel
      • 9.5.7.5 Analyst View
    • 9.5.8 Revvity Inc.
      • 9.5.8.1 Overview
      • 9.5.8.2 Top Products
      • 9.5.8.3 Top Competitors
      • 9.5.8.4 Key Personnel
      • 9.5.8.5 Analyst View
    • 9.5.9 QIAGEN N.V.
      • 9.5.9.1 Overview
      • 9.5.9.2 Top Products
      • 9.5.9.3 Top Competitors
      • 9.5.9.4 Key Personnel
      • 9.5.9.5 Analyst View
    • 9.5.10 Danaher Corporation
      • 9.5.10.1 Overview
      • 9.5.10.2 Top Products
      • 9.5.10.3 Top Competitors
      • 9.5.10.4 Key Personnel
      • 9.5.10.5 Analyst View
    • 9.5.11 SOPHiA GENETICS SA
      • 9.5.11.1 Overview
      • 9.5.11.2 Top Products
      • 9.5.11.3 Top Competitors
      • 9.5.11.4 Key Personnel
      • 9.5.11.5 Analyst View
    • 9.5.12 New England Biolabs
      • 9.5.12.1 Overview
      • 9.5.12.2 Top Products
      • 9.5.12.3 Top Competitors
      • 9.5.12.4 Key Personnel
      • 9.5.12.5 Analyst View

10 Research Methodology

  • 10.1 Data Sources
    • 10.1.1 Primary Data Sources
    • 10.1.2 Secondary Data Sources
    • 10.1.3 Data Triangulation
  • 10.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Latin America Short- and Long-Read NGS Market (by Scenario), $Million, 2024, 2030, and 2036
  • Figure 2: Latin America Short- and Long-Read NGS Market (Short-Read NGS, by Product Type), $Million, 2025, 2030, and 2036
  • Figure 3: Latin America Short- and Long-Read NGS Market (Long-Read NGS, by Product Type), $Million, 2025, 2030, and 2036
  • Figure 4: Latin America Short- and Long-Read NGS Market (by Workflow), $Million, 2025, 2030, and 2036
  • Figure 5: Latin America Short- and Long-Read NGS Market (by Technology), $Million, 2025, 2030, and 2036
  • Figure 6: Latin America Short- and Long-Read NGS Market (by Method), $Million, 2025, 2030, and 2036
  • Figure 7: Latin America Short- and Long-Read NGS Market (by Application), $Million, 2025, 2030, and 2036
  • Figure 8: Latin America Short- and Long-Read NGS Market (by End User), $Million, 2025, 2030, and 2036
  • Figure 9: Short- and Long-Read NGS Ecosystem
  • Figure 10: NGS Workflow
  • Figure 11: Regulatory Landscape for Brazil
  • Figure 12: Regulatory Landscape for Mexico
  • Figure 13: Regulatory Landscape for Argentina
  • Figure 14: Regulatory Landscape for Colombia
  • Figure 15: Short- and Long-Read NGS Market, Patent Analysis (by Year), 2023-2025
  • Figure 16: Short- and Long-Read NGS Market, Patent Analysis (by Country), 2023-2025
  • Figure 17: Latin America Short- and Long-Read NGS Market, Genomics Research and Funding Initiatives (by Country), 2023-2026
  • Figure 18: Latin America Short- and Long-Read NGS Market, Genomics Research and Funding Initiatives (by Institution Type), 2023-2026
  • Figure 19: Latin America Short- and Long-Read NGS Market, Genomics Research and Funding Initiatives (by Research Area), 2023-2026
  • Figure 20: Emerging Technology Trends in Latin America
  • Figure 21: Growth of Long-Read Sequencing in Latin America
  • Figure 22: AI and Bioinformatics Integration across the NGS Workflow
  • Figure 23: Market Opportunities for Latin America Short- and Long-Read NGS Market
  • Figure 24: Latin America Cancer Statistics, 2022-2050
  • Figure 25: Latin America Short- and Long-Read NGS Market (by Product Type), $Million, 2025, 2030, and 2036
  • Figure 26: Latin America Short- and Long-Read NGS Market (Short-Read NGS Market), $Million, 2024-2036
  • Figure 27: Latin America Short- and Long-Read NGS Market (Consumables), $Million, 2024-2036
  • Figure 28: Latin America Short- and Long-Read NGS Market (Instruments), $Million, 2024-2036
  • Figure 29: Latin America Short- and Long-Read NGS Market (Software), $Million, 2024-2036
  • Figure 30: Latin America Short- and Long-Read NGS Market (Long-Read NGS Market), $Million, 2024-2036
  • Figure 31: Latin America Short- and Long-Read NGS Market (Consumables), $Million, 2024-2036
  • Figure 32: Latin America Short- and Long-Read NGS Market (Instruments), $Million, 2024-2036
  • Figure 33: Latin America Short- and Long-Read NGS Market (Software), $Million, 2024-2036
  • Figure 34: Latin America Short- and Long-Read NGS Market (by Workflow), $Million, 2025, 2030, and 2036
  • Figure 35: Latin America Short- and Long-Read NGS Market (Sample and Library Preparation), $Million, 2024-2036
  • Figure 36: Latin America Short- and Long-Read NGS Market (Sequencing), $Million, 2024-2036
  • Figure 37: Latin America Short- and Long-Read NGS Market (Data Analysis), $Million, 2024-2036
  • Figure 38: Latin America Short- and Long-Read NGS Market (by Technology), $Million, 2025, 2030, and 2036
  • Figure 39: Latin America Short- and Long-Read NGS Market (Short-Read Sequencing Technologies), $Million, 2024-2036
  • Figure 40: Latin America Short- and Long-Read NGS Market (Sequencing by Synthesis), $Million, 2024-2036
  • Figure 41: Latin America Short- and Long-Read NGS Market (Semiconductor Sequencing), $Million, 2024-2036
  • Figure 42: Latin America Short- and Long-Read NGS Market (DNA Nanoball Sequencing), $Million, 2024-2036
  • Figure 43: Latin America Short- and Long-Read NGS Market (Long-Read Sequencing Technologies), $Million, 2024-2036
  • Figure 44: Latin America Short- and Long-Read NGS Market (Single-Molecule Real-Time Sequencing), $Million, 2024-2036
  • Figure 45: Latin America Short- and Long-Read NGS Market (Nanopore Sequencing), $Million, 2024-2036
  • Figure 46: Latin America Short- and Long-Read NGS Market (by Method), $Million, 2025, 2030, and 2036
  • Figure 47: Latin America Short- and Long-Read NGS Market (Whole-Genome Sequencing), $Million, 2024-2036
  • Figure 48: Latin America Short- and Long-Read NGS Market (Whole-Exome Sequencing), $Million, 2024-2036
  • Figure 49: Latin America Short- and Long-Read NGS Market (RNA Sequencing), $Million, 2024-2036
  • Figure 50: Latin America Short- and Long-Read NGS Market (Epigenetic Sequencing), $Million, 2024-2036
  • Figure 51: Latin America Short- and Long-Read NGS Market (Targeted Sequencing), $Million, 2024-2036
  • Figure 52: Latin America Short- and Long-Read NGS Market (Metagenomics), $Million, 2024-2036
  • Figure 53: Latin America Short- and Long-Read NGS Market (Others), $Million, 2024-2036
  • Figure 54: Latin America Short- and Long-Read NGS Market (by Application), $Million, 2025, 2030, and 2036
  • Figure 55: Latin America Short- and Long-Read NGS Market (Research), $Million, 2024-2036
  • Figure 56: Latin America Short- and Long-Read NGS Market (Oncology), $Million, 2024-2036
  • Figure 57: Latin America Short- and Long-Read NGS Market (Population Genomics), $Million, 2024-2036
  • Figure 58: Latin America Short- and Long-Read NGS Market (Infectious Diseases), $Million, 2024-2036
  • Figure 59: Latin America Short- and Long-Read NGS Market (Microbiome Research), $Million, 2024-2036
  • Figure 60: Latin America Short- and Long-Read NGS Market (Other Research Applications), $Million, 2024-2036
  • Figure 61: Latin America Short- and Long-Read NGS Market (Clinical), $Million, 2024-2036
  • Figure 62: Latin America Short- and Long-Read NGS Market (Oncology), $Million, 2024-2036
  • Figure 63: Latin America Short- and Long-Read NGS Market (Hematologic Malignancies), $Million, 2024-2036
  • Figure 64: Latin America Short- and Long-Read NGS Market (Solid Tumors), $Million, 2024-2036
  • Figure 65: Latin America Short- and Long-Read NGS Market (Cardiovascular), $Million, 2024-2036
  • Figure 66: Latin America Short- and Long-Read NGS Market (Neurological), $Million, 2024-2036
  • Figure 67: Latin America Short- and Long-Read NGS Market (Inherited Genetic Diseases), $Million, 2024-2036
  • Figure 68: Latin America Short- and Long-Read NGS Market (Infectious Diseases), $Million, 2024-2036
  • Figure 69: Latin America Short- and Long-Read NGS Market (Reproductive Health and Prenatal), $Million, 2024-2036
  • Figure 70: Latin America Short- and Long-Read NGS Market (Other Clinical Applications), $Million, 2024-2036
  • Figure 71: Latin America Short- and Long-Read NGS Market (by End User), $Million, 2025, 2030, and 2036
  • Figure 72: Latin America Short- and Long-Read NGS Market (Hospitals and Diagnostic Centers), $Million, 2024-2036
  • Figure 73: Latin America Short- and Long-Read NGS Market (Academic and Research Institutes), $Million, 2024-2036
  • Figure 74: Latin America Short- and Long-Read NGS Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2036
  • Figure 75: Latin America Short- and Long-Read NGS Market (Other End Users), $Million, 2024-2036
  • Figure 76: Brazil Short- and Long-Read NGS Market, $Million, 2024-2036
  • Figure 77: Brazil Short- and Long-Read NGS Market, Installed Base, 2024-2036
  • Figure 78: Mexico Short- and Long-Read NGS Market, $Million, 2024-2036
  • Figure 79: Mexico Short- and Long-Read NGS Market, Installed Base, 2024-2036
  • Figure 80: Argentina Short- and Long-Read NGS Market, $Million, 2024-2036
  • Figure 81: Argentina Short- and Long-Read NGS Market, Installed Base, 2024-2036
  • Figure 82: Chile Short- and Long-Read NGS Market, $Million, 2024-2036
  • Figure 83: Chile Short- and Long-Read NGS Market, Installed Base, 2024-2036
  • Figure 84: Colombia Short- and Long-Read NGS Market, $Million, 2024-2036
  • Figure 85: Colombia Short- and Long-Read NGS Market, Installed Base, 2024-2036
  • Figure 86: Rest-of-Latin America Short- and Long-Read NGS Market, $Million, 2024-2036
  • Figure 87: Rest-of-Latin America Short- and Long-Read NGS Market, Installed Base, 2024-2036
  • Figure 88: Data Triangulation
  • Figure 89: Top-Down and Bottom-Up Approach
  • Figure 90: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Approval Timelines, License Validity, and Fees for Medical Devices
  • Table 3: NGS Instrument Average Selling Price
  • Table 4: NGS Kits Average Selling Price
  • Table 5: Some of the Key Developments across Latin America
  • Table 6: Latin America Short- and Long-Read NGS Market (by Region), $Million, 2024-2036
  • Table 7: Brazil Short- and Long-Read NGS Market (by Product Type), $Million, 2024-2036
  • Table 8: Brazil Short- and Long-Read NGS Market (by Technology), $Million, 2024-2036
  • Table 9: Brazil Short- and Long-Read NGS Market (by Workflow), $Million, 2024-2036
  • Table 10: Brazil Short- and Long-Read NGS Market (by Application), $Million, 2024-2036
  • Table 11: Brazil Short- and Long-Read NGS Market (by Method), $Million, 2024-2036
  • Table 12: Brazil Short- and Long-Read NGS Market, Testing Volume, 2024-2036
  • Table 13: Brazil Short- and Long-Read NGS Market, Testing Volume (by Outsourced Testing), 2024-2036
  • Table 14: Brazil Short- and Long-Read NGS Market, Testing Volume (by Local Testing), 2024-2036
  • Table 15: Mexico Short- and Long-Read NGS Market (by Product Type), $Million, 2024-2036
  • Table 16: Mexico Short- and Long-Read NGS Market (by Technology), $Million, 2024-2036
  • Table 17: Mexico Short- and Long-Read NGS Market (by Workflow), $Million, 2024-2036
  • Table 18: Mexico Short- and Long-Read NGS Market (by Application), $Million, 2024-2036
  • Table 19: Mexico Short- and Long-Read NGS Market (by Method), $Million, 2024-2036
  • Table 20: Mexico Short- and Long-Read NGS Market, Testing Volume, 2024-2036
  • Table 21: Mexico Short- and Long-Read NGS Market, Testing Volume (by Outsourced Testing), 2024-2036
  • Table 22: Mexico Short- and Long-Read NGS Market, Testing Volume (by Local Testing), 2024-2036
  • Table 23: Argentina Short- and Long-Read NGS Market (by Product Type), $Million, 2024-2036
  • Table 24: Argentina Short- and Long-Read NGS Market (by Technology), $Million, 2024-2036
  • Table 25: Argentina Short- and Long-Read NGS Market (by Workflow), $Million, 2024-2036
  • Table 26: Argentina Short- and Long-Read NGS Market (by Application), $Million, 2024-2036
  • Table 27: Argentina Short- and Long-Read NGS Market (by Method), $Million, 2024-2036
  • Table 28: Argentina Short- and Long-Read NGS Market, Testing Volume, 2024-2036
  • Table 29: Argentina Short- and Long-Read NGS Market, Testing Volume (by Outsourced Testing), 2024-2036
  • Table 30: Argentina Short- and Long-Read NGS Market, Testing Volume (by Local Testing), 2024-2036
  • Table 31: Chile Short- and Long-Read NGS Market (by Product Type), $Million, 2024-2036
  • Table 32: Chile Short- and Long-Read NGS Market (by Technology), $Million, 2024-2036
  • Table 33: Chile Short- and Long-Read NGS Market (by Workflow), $Million, 2024-2036
  • Table 34: Chile Short- and Long-Read NGS Market (by Application), $Million, 2024-2036
  • Table 35: Chile Short- and Long-Read NGS Market (by Method), $Million, 2024-2036
  • Table 36: Chile Short- and Long-Read NGS Market, Testing Volume, 2024-2036
  • Table 37: Chile Short- and Long-Read NGS Market, Testing Volume (by Outsourced Testing), 2024-2036
  • Table 38: Chile Short- and Long-Read NGS Market, Testing Volume (by Local Testing), 2024-2036
  • Table 39: Colombia Short- and Long-Read NGS Market (by Product Type), $Million, 2024-2036
  • Table 40: Colombia Short- and Long-Read NGS Market (by Technology), $Million, 2024-2036
  • Table 41: Colombia Short- and Long-Read NGS Market (by Workflow), $Million, 2024-2036
  • Table 42: Colombia Short- and Long-Read NGS Market (by Application), $Million, 2024-2036
  • Table 43: Colombia Short- and Long-Read NGS Market (by Method), $Million, 2024-2036
  • Table 44: Colombia Short- and Long-Read NGS Market, Testing Volume, 2024-2036
  • Table 45: Colombia Short- and Long-Read NGS Market, Testing Volume (by Outsourced Testing), 2024-2036
  • Table 46: Colombia Short- and Long-Read NGS Market, Testing Volume (by Local Testing), 2024-2036
  • Table 47: Rest-of-Latin America Short- and Long-Read NGS Market (by Product Type), $Million, 2024-2036
  • Table 48: Rest-of-Latin America Short- and Long-Read NGS Market (by Technology), $Million, 2024-2036
  • Table 49: Rest-of-Latin America Short- and Long-Read NGS Market (by Workflow), $Million, 2024-2036
  • Table 50: Rest-of-Latin America Short- and Long-Read NGS Market (by Application), $Million, 2024-2036
  • Table 51: Rest-of-Latin America Short- and Long-Read NGS Market (by Method), $Million, 2024-2036
  • Table 52: Rest-of-Latin America Short- and Long-Read NGS Market, Testing Volume, 2024-2036
  • Table 53: Rest-of-Latin America Short- and Long-Read NGS Market, Testing Volume (by Outsourced Testing), 2024-2036
  • Table 54: Rest-of-Latin America Short- and Long-Read NGS Market, Testing Volume (by Local Testing), 2024-2036
  • Table 55: Latin America Short- and Long-Read NGS Market, Company Share (by Short-Read Technology), 2025
  • Table 56: Latin America Short- and Long-Read NGS Market, Company Share (by Long-Read Technology), 2025
  • Table 57: Comparison of Some of the Key Sequencers
  • Table 58: Latin America Short- and Long-Read NGS Market, Product Benchmarking (by Product Type)
  • Table 59: Latin America Short- and Long-Read NGS Market, Product Benchmarking (by Technology)
  • Table 60: Key NGS Facilities in Latin America
  • Table 61: Some of the Major Key Strategies, January 2023-June 2026